Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Nuvectis Pharma
(NVCT)
NASDAQ
:NVCT
NVCT
Nuvectis Pharma
Overview
Analyst Forecasts
AI Stock Analysis
Popular
Dividends
Earnings
Ownership
Financials
Statistics
New
Technical Analysis
Historical Prices
New
News & Insights
Chart
Drug Pipeline
More
RESEARCH TOOLS
Top Analyst Stocks
Top Smart Score Stocks
Stock Screener
reports
Nuvectis Pharma (NVCT) Stock News & Sentiment
Compare
Follow
118
Followers
Premium
Ratings
Nuvectis Pharma: Buy Rating Backed by NXP900’s Potential to Overcome EGFR/ALK Inhibitor Resistance in NSCLC
3M ago
NVCT
Premium
Ratings
Positive Recommendation on Nuvectis Pharma Driven by Promising Lead Candidate and Milestone Clinical Studies
3M ago
NVCT
Premium
Ratings
NXP900: A Promising New Standard in Post-TKI NSCLC Treatment
4M ago
NVCT
Premium
Ratings
Buy Rating for Nuvectis Pharma’s NXP900 Driven by Promising Efficacy and Development Progress
4M ago
NVCT
Premium
Company Announcements
Nuvectis Pharma Reports Progress in Oncology Drug Development
5M ago
NVCT
Premium
Company Announcements
Nuvectis Pharma’s Phase 1 Study of NXP900: A Potential Game-Changer in Cancer Treatment
5M ago
NVCT
Premium
Ratings
Promising Safety and Efficacy of Nuvectis Pharma’s NXP900 Drives Buy Recommendation
5M ago
NVCT
More NVCT News >
NVCT News on the Web
All News
Bearish News
Bullish News
2026-03-19
Nuvectis Pharma management to meet with Maxim
TipRanks News
Neutral
2026-02-13
Nuvectis Pharma (NVCT) Files $150 Million Mixed Securities Shelf
GuruFocus News
Neutral
2026-02-13
Nuvectis Pharma files $150M mixed securities shelf
TipRanks News
Neutral
2026-02-12
Analysts Offer Insights on Healthcare Companies: Nuvectis Pharma (NVCT), Tenet Healthcare (THC) and Upstream Bio, Inc. (UPB)
TipRanks News
Bullish
2026-02-11
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks News
Bullish
2026-01-08
Why Nuvectis Pharma, Inc.’s (NVCT) Stock Is Up 6.54%
AAII
Neutral
2026-01-02
Why Nuvectis Pharma, Inc.’s (NVCT) Stock Is Up 6.36%
AAII
Neutral
2025-12-23
Why Nuvectis Pharma, Inc.’s (NVCT) Stock Is Down 5.33%
AAII
Neutral
81
Results | Showing
1
out of
11
News Score - Last 7 Days
Neutral
NVCT
Sector Average
Media Buzz
This Week
1 articles
Weekly Average
1 articles
News Sentiment
This Week
50%
Sector Average
67%
See how Bullish or Bearish a stock is based on its recent media coverage.
This score is generated using a formula that combines
Media Buzz
and
News Sentiment
.
Media Coverage Analysis
The historical news coverage of this asset in the last three months.
FAQ
What is NVCT’s Media Buzz Sentiment?
1 articles about NVCT were published this week. In an average week, 1 articles are published.
What is NVCT’s weekly average amount of articles?
In an average week, 1 articles about NVCT are published.
What is NVCT’s News Sentiment?
50% of articles about NVCT were positive this week, compared to its sector average of 67%.
Healthcare Stocks that are Trending in the News
KHTRF
Knight Therapeutics
ABOS
Acumen Pharmaceuticals
KMTS
Kestra Medical Technologies Ltd.
MIST
Milestone Pharmaceuticals
OVID
Ovid Therapeutics
Showing the stocks with the most bullish news sentiment over the past week
See the stocks with the most bullish news sentiment in the sector
Upgrade Now
You need to enable JavaScript to run this app.